Arne Simon1,2, Markus Mock3, Norbert Graf4, Lutz von Müller3. 1. Pediatric Oncology and Hematology, Saarland University Hospital, Saar, Homburg, Germany. Arne.Simon@uks.eu. 2. Klinik für Pädiatrische Onkologie und Hämatologie, Universitätsklinikum des Saarlandes, Kirrberger Straße, Gebäude 9 Saar, 66421, Homburg, Germany. Arne.Simon@uks.eu. 3. Institute of Medical Microbiology and Hygiene, National Consultant Laboratory for Clostridium difficile, University of Saarland Medical Centre, Homburg, Germany. 4. Pediatric Oncology and Hematology, Saarland University Hospital, Saar, Homburg, Germany.
Abstract
In a German pediatric oncology unit, the attending physicians diagnosed 27 cases of Clostridium difficile-associated disease (CDI) from January 01, 2010 to October 31, 2013. This refers to a CDI incidence density of 2.0/1000 inpatient days. According to the hospital hygiene standard, symptomatic patients with CDI were kept in contact isolation. Most patients (median age 8.2 years) suffered from acute lymphoblastic leukemia; 88.9% were treated with broad-spectrum antibiotics during the preceding 4 weeks. 29.6% received intravenous morphine/metamizole and parenteral nutrition due to severe chemotherapy-induced mucositis. None of the patients experienced severe complications such as lower gastrointestinal tract bleeding, sepsis, or toxic megacolon. Genotyping of the isolates derived from symptomatic patients revealed many different ribotypes without detection of the hypervirulent 027 strain and did not point at hospital transmission as an important promoter of CDI in our unit. CONCLUSION: Under strict standard hygiene and contact isolation for symptomatic patients, genotyping of clinical isolates revealed that in pediatric cancer patients, CDI is not necessarily based on nosocomial transmission. The rate of CDI-related severe complications was low. What is Known: • Pediatric cancer patients face an increased risk of Clostridium difficile-associated disease due to immunosuppression, cancer chemotherapy, mucositis, and dysbiosis following intravenous broad-spectrum antimicrobial treatment. • C. difficile may be transmitted from patient to patient. What is New: • Under strict standard hygiene and contact isolation for symptomatic patients, genotyping of clinical isolates revealed that in pediatric cancer patients, CDI is not necessarily based on nosocomial transmission. • The rate of CDI-related severe complications was low.
In a German pediatric oncology unit, the attending physicians diagnosed 27 cases of Clostridium difficile-associated disease (CDI) from January 01, 2010 to October 31, 2013. This refers to a CDI incidence density of 2.0/1000 inpatient days. According to the hospital hygiene standard, symptomatic patients with CDI were kept in contact isolation. Most patients (median age 8.2 years) suffered from acute lymphoblastic leukemia; 88.9% were treated with broad-spectrum antibiotics during the preceding 4 weeks. 29.6% received intravenous morphine/metamizole and parenteral nutrition due to severe chemotherapy-induced mucositis. None of the patients experienced severe complications such as lower gastrointestinal tract bleeding, sepsis, or toxic megacolon. Genotyping of the isolates derived from symptomatic patients revealed many different ribotypes without detection of the hypervirulent 027 strain and did not point at hospital transmission as an important promoter of CDI in our unit. CONCLUSION: Under strict standard hygiene and contact isolation for symptomatic patients, genotyping of clinical isolates revealed that in pediatric cancerpatients, CDI is not necessarily based on nosocomial transmission. The rate of CDI-related severe complications was low. What is Known: • Pediatric cancerpatients face an increased risk of Clostridium difficile-associated disease due to immunosuppression, cancer chemotherapy, mucositis, and dysbiosis following intravenous broad-spectrum antimicrobial treatment. • C. difficile may be transmitted from patient to patient. What is New: • Under strict standard hygiene and contact isolation for symptomatic patients, genotyping of clinical isolates revealed that in pediatric cancerpatients, CDI is not necessarily based on nosocomial transmission. • The rate of CDI-related severe complications was low.
Authors: Judith A Guzman-Cottrill; Karen A Ravin; Kristina A Bryant; Danielle M Zerr; Larry Kociolek; Jane D Siegel Journal: Infect Control Hosp Epidemiol Date: 2013-09-04 Impact factor: 3.254
Authors: Julia Shaklee Sammons; Jeffrey S Gerber; Pranita D Tamma; Thomas J Sandora; Susan E Beekmann; Philip M Polgreen; Adam L Hersh Journal: J Pediatric Infect Dis Soc Date: 2013-10-17 Impact factor: 3.164
Authors: Michel J van Vliet; Wim J E Tissing; Catharina A J Dun; Nico E L Meessen; Willem A Kamps; Eveline S J M de Bont; Hermie J M Harmsen Journal: Clin Infect Dis Date: 2009-07-15 Impact factor: 9.079
Authors: Raymund Dantes; Erin E Epson; Samuel R Dominguez; Susan Dolan; Frank Wang; Amanda Hurst; Sarah K Parker; Helen Johnston; Kelly West; Lydia Anderson; James K Rasheed; Heather Moulton-Meissner; Judith Noble-Wang; Brandi Limbago; Elaine Dowell; Joanne M Hilden; Alice Guh; Lori A Pollack; Carolyn V Gould Journal: Am J Infect Control Date: 2015-10-23 Impact factor: 2.918
Authors: Maribeth R Nicholson; Isaac P Thomsen; James C Slaughter; C Buddy Creech; Kathryn M Edwards Journal: J Pediatr Gastroenterol Nutr Date: 2015-01 Impact factor: 2.839
Authors: Lutz von Müller; Markus Mock; Alexander Halfmann; Julia Stahlmann; Arne Simon; Mathias Herrmann Journal: Int J Med Microbiol Date: 2015-08-22 Impact factor: 3.473
Authors: Nicole M Boyle; Amalia Magaret; Zach Stednick; Alex Morrison; Susan Butler-Wu; Danielle Zerr; Karin Rogers; Sara Podczervinski; Anqi Cheng; Anna Wald; Steven A Pergam Journal: Antimicrob Resist Infect Control Date: 2015-10-14 Impact factor: 4.887
Authors: Thomas Lehrnbecher; Robert Phillips; Sarah Alexander; Frank Alvaro; Fabianne Carlesse; Brian Fisher; Hana Hakim; Maria Santolaya; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Faith Gibson; Andreas H Groll; Aditya Gaur; Ajay Gupta; Rejin Kebudi; Sérgio Petrilli; William J Steinbach; Milena Villarroel; Theoklis Zaoutis; Lillian Sung Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544